Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 26, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references an employee stock purchase plan
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002013156-26-000002
Filed / recorded
Mar 3, 2026, 3:22 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Jazz Pharmaceuticals plc
Issuer CIK
1232524
Ticker
JAZZ
Reporting person
Philip L Johnson
Relationship
Officer
Officer title
EVP & Chief Financial Officer
Security
Ordinary Shares
Table
Non-derivative (Table I)
Transaction date
Feb 26, 2026
Transaction code
A
Shares / units
11,857
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
62,223
Ownership form
Direct
Amendment
No
Footnotes from the filing
These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
The Reporting Person acquired 166 ordinary shares on May 30, 2025 and 140 shares on November 28, 2025 under a Section 423 Employee Stock Purchase Plan.